AAPL325.89-1.85 (-0.56%) ▼|ABBV253.30-2.80 (-1.09%) ▼|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|AAPL325.89-1.85 (-0.56%) ▼|ABBV253.30-2.80 (-1.09%) ▼|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|
24.9 C
New York
Thursday, July 23, 2026

Tag: osteoarthritis

newssourceFORcompanyinformationcontent1releasesmarket

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /CNW/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

Surgical Devices Market worth $296.76 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Surgical Devices Market is projected to grow from about USD 188.74 billion...

12 Press Releases You Need to See This Week

Including TIME's list of the most influential people in sports, a SPAM x Hello Kitty collab and the latest retatrutide results from Lilly.Plus, recapping...

Age is just a Number. Mobility is a Choice.

Robotics at Zydus Hospitals, Gujarat are revolutionising Joint Replacement Surgeries in the ElderlyAHMEDABAD, India, June 11, 2026 /PRNewswire/ -- Osteoarthritis and chronic joint degeneration affect...

Rapid Nutrition Featured on CNBC Discussing Key Trends Shaping the Future of Consumer Wellness

CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving consumer wellness landscape 
CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving consumer wellness landscape

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOsteoarthritis

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers